Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Dosage Forms × Lymphoid × Clear all

Phase

Phase 2/3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 CNS 1

Conditions

Interventions

Rituximab 135 Cyclophosphamide 132 fludarabine 65 Lenalidomide 59 Vincristine 58 fludarabine phosphate 52 Etoposide 48 Doxorubicin 46 venetoclax 43 Prednisone 43 Cytarabine 37 Dexamethasone 35 Peripheral Blood Stem Cell Transplantation 33 Filgrastim 31 obinutuzumab 30 Methotrexate 30 Bendamustine Hydrochloride 30 ibrutinib 28 Gemcitabine 28 Melphalan 23 Bortezomib 23 pembrolizumab 20 Alemtuzumab 20 Whole-Body Irradiation 18 Carboplatin 18 Radiotherapy 17 Busulfan 17 Tacrolimus 16 Mycophenolic Acid 16 Ifosfamide 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03593187 2025-11-20

GENHIV

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Completed

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡